| USGOV-DEPARTMENT-OF-VETERANS-AFFAIRS |
USGOV-DEPARTMENT-OF-VETERANS-AFFAIRS |
95%
|
USAspending awards from Department of Veterans Affairs: $84,400 across 1 awards. 36C26024P0864 GENETIC TESTING FOR VA PORTLAND HEALTH CARE SYSTEM | Qwen corrected direction: Explicit government contr… |
| LABORATORY-CUSTOMER |
LABORATORY-CUSTOMER |
92%
|
For the laboratory services segment, when customers who, to our knowledge, are under common control or otherwise affiliated with each other are aggregated, one of our laboratory customers contributed… |
| ABT |
Abbott Laboratories |
72%
|
supplier of the next generation sequencers and associated reagents we use to perform our genetic tests and as the sole provider of maintenance and repair services for these sequencers; on Roche Holdi… |
| ABT |
Abbott Laboratories |
72%
|
Reciprocal relationship from ABT graph: Reciprocal relationship from FLGT graph: Reciprocal relationship from ABT graph: Reciprocal relationship from FLGT graph: supplier of the next generation seque… |
| DGX |
Quest Diagnostics Incorporated |
72%
|
Reciprocal relationship from DGX graph: Reciprocal relationship from FLGT graph: , information technology, and service companies may develop and sell competitive tests, which may include informatics … |
| DGX |
Quest Diagnostics Incorporated |
72%
|
, information technology, and service companies may develop and sell competitive tests, which may include informatics analysis, integrated genetic tools, and services for health and wellness. We also… |
| EXAS |
Exact Sciences Corp |
72%
|
Reciprocal relationship from EXAS graph: Reciprocal relationship from FLGT graph: supplier of the next generation sequencers and associated reagents we use to perform our genetic tests and as the sol… |
| EXAS |
Exact Sciences Corp |
72%
|
supplier of the next generation sequencers and associated reagents we use to perform our genetic tests and as the sole provider of maintenance and repair services for these sequencers; on Roche Holdi… |
| FISI |
Financial Institutions, Inc. |
72%
|
ly those with life-threatening illnesses, resulting from adverse reactions to the drugs administered during testing or after product launch, respectively. Although we maintain the types and amounts o… |
| FISI |
Financial Institutions, Inc. |
72%
|
Reciprocal relationship from FISI graph: Reciprocal relationship from FLGT graph: ly those with life-threatening illnesses, resulting from adverse reactions to the drugs administered during testing o… |
| GH |
Guardant Health, Inc. |
72%
|
Reciprocal relationship from GH graph: Reciprocal relationship from FLGT graph: ry equipment, supplies, and services for our flow cytometry tests and testing services; on Leica Biosystems for an auto… |
| GH |
Guardant Health, Inc. |
72%
|
ry equipment, supplies, and services for our flow cytometry tests and testing services; on Leica Biosystems for an automated digital scanning solution to scale up digital pathology operations; and on… |
| MYGN |
Myriad Genetics, Inc. |
72%
|
Reciprocal relationship from MYGN graph: Reciprocal relationship from FLGT graph: Reciprocal relationship from MYGN graph: Reciprocal relationship from FLGT graph: , information technology, and servi… |
| MYGN |
Myriad Genetics, Inc. |
72%
|
, information technology, and service companies may develop and sell competitive tests, which may include informatics analysis, integrated genetic tools, and services for health and wellness. We also… |
| TEM |
Tempus AI, Inc. |
72%
|
Reciprocal relationship from TEM graph: Reciprocal relationship from FLGT graph: Reciprocal relationship from TEM graph: Reciprocal relationship from FLGT graph: Reciprocal relationship from TEM grap… |
| TEM |
Tempus AI, Inc. |
72%
|
supplier of the next generation sequencers and associated reagents we use to perform our genetic tests and as the sole provider of maintenance and repair services for these sequencers; on Roche Holdi… |
| WGS |
GeneDx Holdings Corp. |
72%
|
Reciprocal relationship from WGS graph: Reciprocal relationship from FLGT graph: Reciprocal relationship from WGS graph: Reciprocal relationship from FLGT graph: Reciprocal relationship from WGS grap… |
| WGS |
GeneDx Holdings Corp. |
72%
|
supplier of the next generation sequencers and associated reagents we use to perform our genetic tests and as the sole provider of maintenance and repair services for these sequencers; on Roche Holdi… |
| AMERICA-HOLDINGS |
AMERICA-HOLDINGS |
62%
|
re, information technology, and service companies may develop and sell competitive tests, which may include informatics analysis, integrated genetic tools, and services for health and wellness. We al… |
| ANP-TECHNOLOGIES-INC |
ANP-TECHNOLOGIES-INC |
62%
|
clude companies making nano drugs such as Bristol-Myers Squibb, academic research institutions, government agencies, and various other public and private research institutions. We believe we compare … |
| CAPITAL-RESOURCES |
CAPITAL-RESOURCES |
62%
|
e attributable, in part, to the nature of our business. Testing demand can often fluctuate throughout the year with lower demand during holiday periods. Our traditional laboratory and testing service… |
| FULGENT-THERAPEUTICS-LLC |
FULGENT-THERAPEUTICS-LLC |
62%
|
ion and $ 1.5 million , respectively, and the noncurrent portion is included in other long-term liabilities in the accompanying Condensed Consolidated Balance Sheets. The interest expense for the thr… |
| HEALTH-RESOURCES |
HEALTH-RESOURCES |
62%
|
ain the low internal costs of our business model, and to record acceptable margins on our sales; • the timing and our ability to develop our drug candidates, to satisfy the U.S. Food and Drug Adminis… |
| INFORM-DIAGNOSTICS-INC |
INFORM-DIAGNOSTICS-INC |
62%
|
n revenue in the three months ended March 31, 2025 . 23 Note 15. Business Combinations Bako Business Combination On March 17, 2026 , or the Bako acquisition date, Inform Diagnostics, Inc., a wholly o… |
| SYMPHONY-BUYER-INC |
SYMPHONY-BUYER-INC |
62%
|
itments with its vendors, which primarily consist of services, reagent and supplies, computer software, and medical lab equipment. As of December 31, 2024, the Company had purchase obligations of $ 4… |
| XILONG-SCIENTIFIC-CO |
XILONG-SCIENTIFIC-CO |
62%
|
xed assets United States $ 98,992 $ 77,938 $ 72,617 Foreign China 4,616 5,526 8,736 Other countries 1,941 — — Total foreign 6,557 5,526 8,736 Total $ 105,549 $ 83,464 $ 81,353 Note 8. Debt, Commitmen… |
